Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
side by side viewer icon HTML

Abstract

Background

Sickle cell anemia (SCA) poses significant metabolic challenges in affected individuals, yet the relationship between resting metabolic rate (RMR) and disease severity remains underexplored, particularly in Sudanese pediatric populations.

Aim

The aim of this study is to investigate the RMR and its correlation with disease severity scores and treatment with hydroxyurea in Sudanese patients with sickle cell disease.

Materials and Methods

We conducted a case-control study on 100 individuals aged 3-18 years, with 50 having SCA and 50 forming the healthy control group. RMR was computed using the Harris-Benedict formula, the World Health Organization equation, and the Buchowski formula. Severity scores were determined using a SCA Scoring System.

Results

The mean age for the control group (9.52 ± 4.35 y) was similar to that of the SCA group, whether receiving or not receiving hydroxyl-urea (9.44 ± 4.164 and 9.68 ± 4.534, respectively (p=0.980). The resting metabolic rate (RMR) in the case group was significantly lower compared to the control group when using the Harris-Benedict and WHO equations (p = 0.004 and 0.001, respectively). A notable difference in RMR was observed between the case group (using the Buchowski formula) and the control group (using the Harris-Benedict equation) (p = 0.006), but not with the WHO equation (p = 0.054). Treatment with hydroxyl-urea was significantly associated with low severity scores among the SCA patients (p< 0.001).

Conclusions

The elevated RMR levels among Sudanese SCA patients compared to healthy subjects can be shown when calculated with the Buchowski formula but not with the other standard equations designed for healthy individuals.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882304598240530102650
2024-06-26
2025-01-31
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882304598.html?itemId=/content/journals/nemj/10.2174/0102506882304598240530102650&mimeType=html&fmt=ahah

References

  1. ElenduC. AmaechiD.C. Alakwe-OjimbaC.E. ElenduT.C. ElenduR.C. AyabazuC.P. AinaT.O. AborisadeO. AdenikinjuJ.S. Understanding Sickle cell disease: Causes, symptoms, and treatment options.Medicine202310238e3523710.1097/MD.000000000003523737746969
    [Google Scholar]
  2. PielF.B. SteinbergM.H. ReesD.C. Sickle cell disease.N. Engl. J. Med.2017376161561157310.1056/NEJMra151086528423290
    [Google Scholar]
  3. BayoumiR.A. ZeidY.A.A. SadigA.A. ElkarimO.A. Sickle cell disease in Sudan.Trans. R. Soc. Trop. Med. Hyg.198882116416810.1016/0035‑9203(88)90298‑22459819
    [Google Scholar]
  4. ConnesP. RenouxC. JolyP. NaderE. Vascular pathophysiology of sickle cell disease.Presse Med.202352410420210.1016/j.lpm.2023.10420237944640
    [Google Scholar]
  5. ReesD.C. WilliamsT.N. GladwinM.T. Sickle-cell disease.Lancet201037697572018203110.1016/S0140‑6736(10)61029‑X21131035
    [Google Scholar]
  6. WangW.C. HelmsR.W. LynnH.S. Redding-LallingerR. GeeB.E. Ohene-FrempongK. Smith-WhitleyK. WaclawiwM.A. VichinskyE.P. StylesL.A. WareR.E. KinneyT.R. Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study.J. Pediatr.2002140222522910.1067/mpd.2002.12138311865275
    [Google Scholar]
  7. HalseyC. RobertsI.A.G. The role of hydroxyurea in sickle cell disease.Br. J. Haematol.2003120217718610.1046/j.1365‑2141.2003.03849.x12542474
    [Google Scholar]
  8. SinghalA. DaviesP. SahotaA. ThomasP.W. SerjeantG.R. Resting metabolic rate in homozygous sickle cell disease.Am. J. Clin. Nutr.1993571323410.1093/ajcn/57.1.327677977
    [Google Scholar]
  9. FungE.B. BardenE.M. KawchakD.A. ZemelB.S. Ohene-FrempongK. StallingsV.A. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.Am. J. Pediatr. Hematol. Oncol.200123960460810.1097/00043426‑200112000‑0001011902305
    [Google Scholar]
  10. FlackK.D. SidersW.A. JohnsonL. RoemmichJ.N. Cross-validation of resting metabolic rate prediction equations.J. Acad. Nutr. Diet.201611691413142210.1016/j.jand.2016.03.01827138231
    [Google Scholar]
  11. BuchowskiM.S. ChenK.Y. ByrneD. WangW.C. Equation to estimate resting energy expenditure in adolescents with sickle cell anemia.Am. J. Clin. Nutr.20027661335134410.1093/ajcn/76.6.133512450901
    [Google Scholar]
  12. AlabidT. KordofaniA.Y. AtallaB. BabekirA. ElaminB.K. Evaluation of clinical severity of sickle cell anemia in Sudanese patients.Am. J. Res. Commun.2016466375
    [Google Scholar]
  13. BorelM.J. BuchowskiM.S. TurnerE.A. PeelerB.B. GoldsteinR.E. FlakollP.J. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease.Am. J. Physiol. Endocrinol. Metab.19982742E357E36410.1152/ajpendo.1998.274.2.E3579486169
    [Google Scholar]
  14. Rankine-MullingsA.E. NevittS.J. Hydroxyurea (hydroxycarbamide) for sickle cell disease.Cochrane Libr.2022202210CD00220210.1002/14651858.CD002202.pub336047926
    [Google Scholar]
  15. DexterD. McGannP.T. Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges.Pharmacotherapy202343543044110.1002/phar.279236906823
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882304598240530102650
Loading
/content/journals/nemj/10.2174/0102506882304598240530102650
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test